Poolbeg Pharma
Poolbeg Pharma is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. Led by a highly experienced management team, the company targets large markets such as cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and obesity with its high-value programmes. It leverages AI-led discovery to identify drug targets and treatments, aiming for faster development and greater commercial appeal. The company actively participates in regulatory news, upcoming events, and maintains a media presence through videos, podcasts, and interviews. Its leadership team includes seasoned experts in biotech and pharma, with a strong emphasis on research, clinical development, regulatory affairs, and strategic partnerships.
Industries
Nr. of Employees
small (1-50)
Poolbeg Pharma
40 Bank Street, Floor 24, London, E14 5NR, United Kingdom.
Products
Orally delivered candidate for prevention of cytokine release syndrome
A development‑stage, orally administered therapeutic candidate intended to prevent immunotherapy‑induced cytokine release syndrome; progressed with human challenge study data and described as Phase 2‑ready in company materials.
Orally encapsulated GLP‑1 development programme
A development programme for an orally encapsulated GLP‑1 receptor agonist intended to address metabolic conditions such as obesity using oral delivery technology.
AI‑derived antiviral candidate programmes (RSV and influenza)
Discovery‑stage antiviral candidates identified through AI analysis of human challenge trial data, focused on respiratory syncytial virus and influenza.
Orally delivered candidate for prevention of cytokine release syndrome
A development‑stage, orally administered therapeutic candidate intended to prevent immunotherapy‑induced cytokine release syndrome; progressed with human challenge study data and described as Phase 2‑ready in company materials.
Orally encapsulated GLP‑1 development programme
A development programme for an orally encapsulated GLP‑1 receptor agonist intended to address metabolic conditions such as obesity using oral delivery technology.
AI‑derived antiviral candidate programmes (RSV and influenza)
Discovery‑stage antiviral candidates identified through AI analysis of human challenge trial data, focused on respiratory syncytial virus and influenza.
Services
Collaborative discovery programmes applying AI/ML to human challenge and clinical datasets to identify antiviral and immunomodulatory targets and candidate molecules.
Negotiation and management of licences to access oral delivery platforms for development of orally administered peptide and small‑molecule therapeutics.
Support for regulatory submissions, protocol development, clinical operations and execution of human challenge studies to generate early clinical data and progress candidates into later‑phase development.
Collaborative discovery programmes applying AI/ML to human challenge and clinical datasets to identify antiviral and immunomodulatory targets and candidate molecules.
Negotiation and management of licences to access oral delivery platforms for development of orally administered peptide and small‑molecule therapeutics.
Support for regulatory submissions, protocol development, clinical operations and execution of human challenge studies to generate early clinical data and progress candidates into later‑phase development.
Expertise Areas
- AI-driven drug discovery
- Human challenge trial design and analysis
- Early‑phase clinical trial management
- Infectious disease therapeutics (respiratory viruses, influenza, RSV)
Key Technologies
- Machine learning / AI for target identification
- Human challenge trial datasets and analysis
- RNA sequencing and genomics analysis
- Oral encapsulation and formulation technologies